Product  Pipeline

Regen has a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs.

Regen BioPharma focuses on creating immune checkpoint medicines.  An immune checkpoint is a mechanism by which certain cells of the immune system, typically T cells, are kept from being fully activated. This type of restraint on the immune system is important in the normal functioning of the immune system. However, it is now well-established that many cancers have an ability to trick immune cells into up-regulating their checkpoints and thus shut down the ability of these immune cells to kill the tumor. Several drugs which target checkpoints, termed checkpoint inhibitors, are currently used as standard of care in certain cancers. Regen has been focusing its research on a novel immune checkpoint called NR2F6
Read More

Regen has a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs.  All of the technologies are protected by multiple granted and pending patents

Product  Pipeline

Regen BioPharma focuses on creating immune checkpoint medicines.  An immune checkpoint is a mechanism by which certain cells of the immune system, typically T cells, are kept from being fully activated.  This type of restraint on the immune system is important in the normal functioning of the immune system.  However, it is now well-established that many cancers have an ability to trick immune cells into up-regulating their checkpoints and thus shut down the ability of these immune cells to kill the tumor.  Several drugs which target checkpoints, termed checkpoint inhibitors, are currently used as standard of care in certain cancers.  Regen has been focusing its research on a novel immune checkpoint called NR2F6.

DuraCAR

Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.

KimerApt

Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.

Read More

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS

HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.

Read More

dCellVax

Breast Cancer – dCellVax – IND #16200

CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”

tCellVax

Solid tumors – tCellVax – IND #16928

tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6 (Solid Tumors).

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC

DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.

Read More

Product  Pipeline

Document
Program
Indication
Milestone
Pre-clinical Testing
IND Submitted
IND Approved
Phase I/II
HemaXcellerate
Personalized Stem Cells
Aplastic Anemia
IND #15376
dCellVax
Gene Silencing of IDO
Breast Cancer
IND #16200
tCellVax
Ex-vivo siRNA NR2F6
Solid Tumors
IND #16928
DiffronC
In vivo siRNA NR2F6
MDS, Solid Tumors
KimerApt
Bi-specific aptamers
Solid Tumors
DuraCAR
Gene-silenced CAR-T cells
Solid and Liquid Tumors